MX365393B - Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. - Google Patents
Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.Info
- Publication number
- MX365393B MX365393B MX2014002942A MX2014002942A MX365393B MX 365393 B MX365393 B MX 365393B MX 2014002942 A MX2014002942 A MX 2014002942A MX 2014002942 A MX2014002942 A MX 2014002942A MX 365393 B MX365393 B MX 365393B
- Authority
- MX
- Mexico
- Prior art keywords
- bendamustine
- formulations
- combination
- histone deacetylase
- deacetylase inhibitor
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002707 bendamustine Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/051470 WO2013039488A1 (en) | 2011-09-13 | 2011-09-13 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002942A MX2014002942A (es) | 2014-09-15 |
| MX365393B true MX365393B (es) | 2019-05-31 |
Family
ID=47883567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002942A MX365393B (es) | 2011-09-13 | 2011-09-13 | Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9492423B2 (enExample) |
| EP (1) | EP2755648B1 (enExample) |
| JP (1) | JP6330118B2 (enExample) |
| KR (1) | KR101892788B1 (enExample) |
| CN (1) | CN103917231B (enExample) |
| AU (1) | AU2011376953B2 (enExample) |
| CA (1) | CA2845806C (enExample) |
| ES (1) | ES2627820T3 (enExample) |
| MX (1) | MX365393B (enExample) |
| NZ (1) | NZ621221A (enExample) |
| RU (1) | RU2609833C2 (enExample) |
| SG (1) | SG2014014419A (enExample) |
| UA (1) | UA110853C2 (enExample) |
| WO (1) | WO2013039488A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2099442T1 (sl) | 2006-12-26 | 2015-03-31 | Pharmacyclics, Inc. | Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju |
| SG2014014419A (en) | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| JP2017537164A (ja) * | 2014-12-05 | 2017-12-14 | ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ |
| JP7366385B2 (ja) * | 2015-06-19 | 2023-10-23 | トラスティーズ オブ ボストン ユニバーシティ | ヘルペスウイルス誘発疾患の処置のための方法および組成物 |
| WO2017175010A1 (en) * | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| MX395521B (es) | 2016-04-08 | 2025-03-25 | Cereno Scient Ab | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas |
| EP3445343A1 (en) * | 2016-04-21 | 2019-02-27 | Valcuria AB | Composition and method for pretreating cancer |
| EP3484489B1 (en) | 2016-07-15 | 2025-06-18 | Viracta Subsidiary, Inc. | Hdac inhibitors for use with nk cell based therapies |
| US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| GB201706544D0 (en) * | 2017-04-25 | 2017-06-07 | Plasticell Ltd | Method |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| TR201900059A2 (tr) | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| AU2019400983B2 (en) | 2018-12-18 | 2025-07-03 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
| KR20220034736A (ko) | 2019-05-31 | 2022-03-18 | 비락타 서브시디어리 인크. | 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법 |
| WO2022159852A1 (en) * | 2021-01-25 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Methods and compositions for treating adenoid cystic carcinoma |
| TW202423402A (zh) * | 2022-10-21 | 2024-06-16 | 美商維拉克塔股份有限公司 | Hdac抑制劑化合物之投藥方法 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3126375A (en) | 1964-03-24 | Chioacyl | ||
| US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
| US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
| US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
| US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
| BE794063A (fr) | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | Anti-inflammatoires pour compositions cosmetiques |
| US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
| SE378109B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| SE378110B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3775656A (en) | 1972-05-22 | 1973-11-27 | Aviat Inc | Platform stabilization system |
| CH581818A5 (enExample) | 1973-02-27 | 1976-11-15 | Cierva Juan J De | |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| EP0084236A3 (en) | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
| US4498038A (en) | 1983-02-15 | 1985-02-05 | Malueg Richard M | Stabilization system for soft-mounted platform |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| JPH0778017B2 (ja) | 1985-12-28 | 1995-08-23 | 住友製薬株式会社 | パルス的かつ持続放出性製剤 |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| EP0394440B1 (en) | 1987-10-20 | 1994-05-11 | Otsuka Pharmaceutical Co., Ltd. | Phenylcarboxylic acid derivatives |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| JPH03215470A (ja) | 1990-01-22 | 1991-09-20 | Suntory Ltd | プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤 |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| DE4124345A1 (de) | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| ES2149781T3 (es) | 1991-11-22 | 2000-11-16 | Procter & Gamble Pharma | Composiciones de risedronato de liberacion retardada. |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| EP0665010B1 (en) | 1992-10-16 | 2002-09-11 | Nippon Shinyaku Company, Limited | Method of manufacturing wax matrices |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
| US5448938A (en) | 1993-10-18 | 1995-09-12 | Guardian Technologies International, Inc. | Removable ballistic resistant armor seat cover and floor mat |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6611662B1 (en) | 1999-05-28 | 2003-08-26 | David E. Grober | Autonomous, self leveling, self correcting stabilized platform |
| US6718130B2 (en) | 1999-05-28 | 2004-04-06 | David E. Grober | Stabilized camera and marker buoy for media coverage of aquatic events |
| EP1204868A1 (en) | 1999-08-10 | 2002-05-15 | Pangene Corporation | Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| WO2001014331A2 (en) | 1999-08-24 | 2001-03-01 | Regents Of The University Of California | Non-quinoline inhibitors of malaria parasites |
| TR200201505T2 (tr) | 1999-09-17 | 2003-01-21 | Abbott Gmbh & Co.Kg | Terapötik maddeler olarak pirazolopirimidinler |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| KR101026205B1 (ko) | 1999-11-23 | 2011-03-31 | 메틸진 인코포레이티드 | 히스톤 디아세틸라제의 억제제 |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| NZ525439A (en) | 2000-09-29 | 2004-11-26 | Topotarget Uk Ltd | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| DE60129043T2 (de) | 2000-12-28 | 2008-02-21 | Epidauros Biotechnologie Ag | Identifizierung von genetischen determinanten der polymorphen cyp3a5 expression |
| MXPA01013172A (es) | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| DK1404304T3 (da) | 2001-06-28 | 2009-07-13 | Ucb Farchim Sa | Tablet omfattende cetirizin og pseudoephedrin |
| US7247426B2 (en) | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| RU2298414C2 (ru) | 2001-08-21 | 2007-05-10 | Астеллас Фарма Инк. | Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030166026A1 (en) | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
| CA2474800A1 (en) | 2002-02-04 | 2003-08-14 | Epidauros Biotechnologie Ag | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications |
| WO2003070691A1 (en) | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| RU2005105696A (ru) | 2002-08-02 | 2005-11-10 | Арджента Дискавери Лимитед (Gb) | Замещенные тиенилгидроксамовые кислоты в качестве ингибиторов гистондеацетилазы |
| EP1400806A1 (en) | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
| US6769347B1 (en) | 2002-11-26 | 2004-08-03 | Recon/Optical, Inc. | Dual elevation weapon station and method of use |
| CA2519320A1 (en) | 2003-02-19 | 2004-09-02 | Astellas Pharma Inc. | Method of estimating antitumor effect of histone deacetylase inhibitor |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ZA200507751B (en) * | 2003-04-07 | 2007-01-31 | Axys Pharm Inc | Novel hydroxamates as therapeutic agents |
| CN102304110A (zh) | 2003-04-07 | 2012-01-04 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| DK2263694T3 (da) | 2003-09-25 | 2013-08-26 | Astellas Pharma Inc | Antitumormiddel omfattende histon-deacetylase-inhibitoren FK228 og topoisomerase-II-inhibitoren doxorubicin |
| EP1682901A2 (en) | 2003-11-04 | 2006-07-26 | Roche Diagnostics GmbH | Method for distinguishing leukemia subtypes |
| WO2005059108A2 (en) | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
| EP1730308A4 (en) | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| WO2005097770A1 (en) | 2004-04-07 | 2005-10-20 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
| ATE399539T1 (de) | 2004-04-30 | 2008-07-15 | Topotarget Germany Ag | Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung |
| CA2569277A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| US20090239214A1 (en) | 2004-07-30 | 2009-09-24 | Hongyue Dai | Prognosis of breast cancer patients |
| WO2006042035A2 (en) | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
| US20060128777A1 (en) | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2006101454A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Benzothiophene derivatives: preparation and pharmaceutical applications |
| WO2007109178A2 (en) | 2006-03-16 | 2007-09-27 | Pharmacyclics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| KR101489947B1 (ko) | 2006-09-15 | 2015-02-04 | 얀센 파마슈티카 엔.브이. | 프로테아좀 억제제와 배합하여, ｉ－형 및 ｉｉｂ－형 히스톤 데아세틸라아제에 결합 활성을 나타내는 히스톤 데아세틸라아제 억제제 |
| SI2099442T1 (sl) | 2006-12-26 | 2015-03-31 | Pharmacyclics, Inc. | Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju |
| US7838234B2 (en) | 2007-01-30 | 2010-11-23 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| UY34295A (es) | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| SG2014014419A (en) | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
-
2011
- 2011-09-13 SG SG2014014419A patent/SG2014014419A/en unknown
- 2011-09-13 WO PCT/US2011/051470 patent/WO2013039488A1/en not_active Ceased
- 2011-09-13 UA UAA201402905A patent/UA110853C2/uk unknown
- 2011-09-13 EP EP11872389.9A patent/EP2755648B1/en active Active
- 2011-09-13 JP JP2014530636A patent/JP6330118B2/ja active Active
- 2011-09-13 NZ NZ621221A patent/NZ621221A/en not_active IP Right Cessation
- 2011-09-13 CA CA2845806A patent/CA2845806C/en active Active
- 2011-09-13 MX MX2014002942A patent/MX365393B/es active IP Right Grant
- 2011-09-13 RU RU2014111069A patent/RU2609833C2/ru not_active IP Right Cessation
- 2011-09-13 US US14/344,314 patent/US9492423B2/en active Active
- 2011-09-13 CN CN201180074826.7A patent/CN103917231B/zh active Active
- 2011-09-13 AU AU2011376953A patent/AU2011376953B2/en active Active
- 2011-09-13 ES ES11872389.9T patent/ES2627820T3/es active Active
- 2011-09-13 KR KR1020147007117A patent/KR101892788B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| UA110853C2 (uk) | 2016-02-25 |
| JP6330118B2 (ja) | 2018-05-30 |
| WO2013039488A1 (en) | 2013-03-21 |
| CN103917231B (zh) | 2016-09-28 |
| RU2014111069A (ru) | 2015-10-20 |
| SG2014014419A (en) | 2014-07-30 |
| MX2014002942A (es) | 2014-09-15 |
| RU2609833C2 (ru) | 2017-02-06 |
| US9492423B2 (en) | 2016-11-15 |
| KR20140073503A (ko) | 2014-06-16 |
| KR101892788B1 (ko) | 2018-08-28 |
| CA2845806C (en) | 2019-06-11 |
| ES2627820T3 (es) | 2017-07-31 |
| EP2755648B1 (en) | 2017-03-08 |
| CA2845806A1 (en) | 2013-03-21 |
| CN103917231A (zh) | 2014-07-09 |
| AU2011376953B2 (en) | 2017-08-24 |
| AU2011376953A1 (en) | 2014-03-06 |
| US20140341989A1 (en) | 2014-11-20 |
| EP2755648A1 (en) | 2014-07-23 |
| EP2755648A4 (en) | 2015-03-11 |
| NZ621221A (en) | 2016-07-29 |
| JP2014526503A (ja) | 2014-10-06 |
| HK1200095A1 (en) | 2015-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365393B (es) | Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. | |
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
| MX375926B (es) | Compuestos y metodos para inhibir el transporte de fosfato. | |
| PH12016501015A1 (en) | Combinations of histone deacetylase inhibitors and immunomodulatory drugs | |
| BR112015000437A2 (pt) | imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| ZA201401117B (en) | Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof | |
| CL2012002026A1 (es) | Compuestos derivados de amidas, inhibidores de hdac6; composicion farmaceutica que los comprende; kit farmaceutico;utiles en el tratamiento del cancer, artritis reumatoide, colitis ulcerativa, enfermedad de crohn, lupus eritematoso,sistemico, entre otras. | |
| IL253911A0 (en) | Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use | |
| HUE036027T2 (hu) | IL17 és IFN-gamma inhibitorok autoimmun gyulladás kezelésére | |
| IL230705A0 (en) | Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| PT2668182T (pt) | Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune | |
| MX2014009892A (es) | Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas. | |
| IL251861A0 (en) | Polyheteroaryl histone deacetylase inhibitors and their use in therapy | |
| LT2922576T (lt) | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai | |
| IL251860A0 (en) | Dithyroaryl histone deacetylase inhibitors and their use in therapy | |
| MX2014004459A (es) | Inhibidores de peptidos de la proteina precursora amiloide de sitio b que escinde la enzima 1 (bace1). | |
| PH12015500069A1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| WO2012024634A3 (en) | Environmentally-responsive nanocomposites and methods of their use | |
| MX2016006058A (es) | Métodos para suprimir caquexia relacionada a cáncer. | |
| PH12012502198A1 (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| HK1240920A1 (en) | Diheteroaryl histone deacetylase inhibitors and their use in therapy | |
| ZA201306087B (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| UA100326U (ru) | Применение натриевой соли гидрогенсульфида для потенцирования анальгетического эффекта нестероидных противовоспалительных препаратов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: PHARMACYCLICS LLC |
|
| GB | Transfer or rights |
Owner name: PHARMACYCLICS LLC |
|
| HC | Change of company name or juridical status |
Owner name: PHARMACYCLICS LLC |
|
| FG | Grant or registration |